Fusion Pharmaceuticals Inc (FUSN)
21.52
+0.03
(+0.14%)
USD |
NASDAQ |
May 22, 16:00
21.53
+0.01
(+0.05%)
After-Hours: 20:00
Fusion Pharmaceuticals Research and Development Expense (Quarterly): 21.31M for March 31, 2024
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2024 | 21.31M |
| December 31, 2023 | 20.65M |
| September 30, 2023 | 14.58M |
| June 30, 2023 | 18.99M |
| March 31, 2023 | 15.88M |
| December 31, 2022 | 17.61M |
| September 30, 2022 | 16.55M |
| June 30, 2022 | 12.08M |
| March 31, 2022 | 12.66M |
| December 31, 2021 | 11.81M |
| September 30, 2021 | 12.68M |
| Date | Value |
|---|---|
| June 30, 2021 | 21.15M |
| March 31, 2021 | 10.72M |
| December 31, 2020 | 4.96M |
| September 30, 2020 | 4.529M |
| June 30, 2020 | 3.325M |
| March 31, 2020 | 4.377M |
| December 31, 2019 | 3.416M |
| September 30, 2019 | 2.238M |
| June 30, 2019 | 2.137M |
| March 31, 2019 | 2.841M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
2.137M
Minimum
Jun 2019
21.31M
Maximum
Mar 2024
11.58M
Average
12.37M
Median
Research and Development Expense (Quarterly) Benchmarks
| AstraZeneca PLC | 2.783B |
| Landos Biopharma Inc | 3.151M |
| Perspective Therapeutics Inc | 7.452M |
| Acasti Pharma Inc | 1.443M |
| Aurinia Pharmaceuticals Inc | 10.23M |